Arcus Biosciences, Inc. vs UnitedHealth Group Incorporated — Stock Comparison
Q·Score Breakdown
5.7
Neutral
Overall
6.3
Neutral
Quality
Health
Growth
Valuation
Sentiment
RCUS
Clean balance sheet with low leverage (0.3× debt-to-equity).
⚠ currently unprofitable (-143% margin).
UNH
82% of 28 covering analysts have a positive rating.
⚠ limited growth momentum.
Analyst Consensus
BUY
Target $34.00 (+32.4%)
10 analysts
BUY
Target $387.27 (+5.0%)
26 analysts
Fundamentals
RCUS
UNH
—
Trailing P/E
27.9×
-7.3×
Forward P/E
17.8×
-142.9%
Profit Margin
2.7%
-111.7%
Gross Margin
18.8%
-63.3%
ROE
12.2%
26.9%
Revenue Growth
2.0%
—
Earnings Growth
0.7%
0.86
Beta
0.41
—
Price / Book
—
$3.2B
Market Cap
$334.9B
$7 – $29
52-Week Range
$235 – $410
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →